Search Results - "Henriquez, Ivan"

A randomised trial of short‐ vs long‐term androgen deprivation with salvage radiotherapy for biochemical failure following radical prostatectomy: URONCOR 06‐24 by González‐San Segundo, Carmen, López Campos, Fernando, Gómez Iturriaga, Alfonso, Rodríguez, Aurora, Olivera, Jesús, Duque‐Santana, Víctor, Sancho, Gemma, Henríquez, Iván, Conde, Antonio José, Valero, Jeannette, Maldonado, Xavier, Glaria, Luis, Caballero, Begoña, Sanmamed, Noelia, Mases, Joel, Boladeras‐Inglada, Anna María, Montijano, Miguel, Santos, Marina, Álvarez, Ana, Martínez, Juan I., Couñago, Felipe

“…Background Salvage radiotherapy (SRT) and androgen‐deprivation therapy (ADT) are widely used in routine clinical practice to treat patients with prostate…”
Get full text

Exeresis and Brachytherapy as Salvage Treatment for Local Recurrence After Conservative Treatment for Breast Cancer: Results of a Ten-Year Pilot Study by Guix, Benjamín, M.D., Ph.D., M.B.A, Lejárcegui, José Antonio, M.D., Ph.D, Tello, José Ignacio, Ph.D, Zanón, Gabriel, M.D, Henríquez, Iván, M.D., Ph.D, Finestres, Fernando, M.D, Martínez, Antonio, M.D, Fernandez-Ibiza, Jaume, M.D, Quinzaños, Luis, M.D, Palombo, Pau, M.D, Encinas, Xavier, M.D, Guix, Inés, B.Ch.Sc

“…Purpose To analyze the long-term results of a pilot study assessing excision and brachytherapy as salvage treatment for local recurrence after conservative…”
Get full text

Clinical Applications of Molecular Biomarkers in Prostate Cancer by Couñago, Felipe, López-Campos, Fernando, Díaz-Gavela, Ana Aurora, Almagro, Elena, Fenández-Pascual, Esaú, Henríquez, Iván, Lozano, Rebeca, Linares Espinós, Estefanía, Gómez-Iturriaga, Alfonso, de Velasco, Guillermo, Quintana Franco, Luis Miguel, Rodríguez-Melcón, Ignacio, López-Torrecilla, José, Spratt, Daniel E., Guerrero, Luis Leonardo, Martínez-Salamanca, Juan Ignacio, del Cerro, Elia

“…There is clinically relevant molecular heterogeneity in prostate cancer (PCa), but this biological diversity has had only a minimal impact on clinical…”
Get full text

Patterns of care and outcome for patients with glioblastoma diagnosed during 2008-2010 in Spain by Graus, Francesc, Bruna, Jordi, Pardo, Javier, Escudero, Domingo, Vilas, Dolores, Barceló, Inés, Brell, Marta, Pascual, Carmen, Crespo, José A, Erro, Elena, García-Romero, Juan C, Estela, Jordi, Martino, Juan, García-Castaño, Almudena, Mata, Elena, Lema, Manuela, Gelabert, Miguel, Fuentes, Rafel, Pérez, Pedro, Manzano, Arancha, Aguas, Jesús, Belenguer, Antonio, Simón, Ana, Henríquez, Iván, Murcia, Mauricio, Vivanco, Rosa, Rojas-Marcos, Iñigo, Muñoz-Carmona, David, Navas, Inmaculada, de Andrés, Pablo, Mas, Gemma, Gil, Miguel, Verger, Eugènia

“…To assess management patterns and outcome in patients with glioblastoma multiforme (GBM) treated during 2008-2010 in Spain. Retrospective analysis of clinical,…”
Get full text

Quality assurance in radiotherapy: analysis of the causes of not starting or early radiotherapy withdrawal by Arenas, Meritxell, Sabater, Sebastià, Gascón, Marina, Henríquez, Ivan, Bueno, M José, Rius, Àngels, Rovirosa, Àngels, Gómez, David, Lafuerza, Anna, Biete, Albert, Colomer, Jordi

“…The aim of this study was to analyse the reasons for not starting or for early of radiotherapy at the Radiation Oncology Department. All radiotherapy…”
Get full text

Dose Escalation with High-Dose-3D-Conformal/IMRT (HD-3D-CRT/IMRT) Compared with Low-Dose 3D-Conformal/IMRT Plus HDR Brachytherapy (LD-3D-CRT/IMRT+HDR-B) for Intermediate- or High-Risk Prostate Cancer: Higher Disease Control and Survival with Lower Toxicity by Guix, Benjamin, MD, PhD, MBA, Bartrina, Jose Maria, MD, PhD, MBA, Guix, Ines, MD, PhD, MBA, Tello, Jose Ignacio, PhD, Henriquez, Ivan, MD, PhD, Quinzanos, Luis, MD, Garcia, Ivan, MD, Mases, Joel, MD, Lacorte, Teresamaria, PhD, Galdon, Guillermo, MD, Guix, Teresa, BCHS

Get full text

Hypofractionated high-dose-rate plesiotherapy in nonmelanoma skin cancer treatment by Arenas, Meritxell, Arguís, Monica, Díez-Presa, Lorena, Henríquez, Ivan, Murcia-Mejía, Mauricio, Gascón, Marina, Gómez, David, Lafuerza, Anna, Mur, Encarna, Azón, Antoni, Rovirosa, Àngels, Sabater, Sebastià

“…Abstract Purpose Nonmelanoma skin cancer (NMSC) is the commonest cancer in humans. NMSC treatment currently includes surgery, radiation therapy, and topical…”
Get full text

Nonmetastatic castration-resistant prostate cancer: Novel agents to treat a lethal disease by Henriquez, Ivan, Spratt, Daniel, Gómez-Iturriaga, Alfonso, Abuchaibe, Oscar, Couñago, Felipe

“…Nonmetastatic castration-resistant prostate cancer (nmCRPC) - defined as prostate-specific antigen (PSA) > 2 ng/mL, testosterone castration levels < 1.7 nm/L,…”
Get full text

Salvage prostate brachytherapy in radiorecurrent prostate cancer: An international Delphi consensus study by Corkum, Mark T., Buyyounouski, Mark K., Chang, Albert J., Chung, Hans T., Chung, Peter, Cox, Brett W., Crook, Juanita M., Davis, Brian J., Frank, Steven J., Henriquez, Ivan, Horwitz, Eric M., Hoskin, Peter, Hsu, I-Chow, Keyes, Mira, King, Martin T., Kollmeier, Marisa A., Krauss, Daniel J., Kukielka, Andrzej M., Morton, Gerard, Orio, Peter F., Pieters, Bradley R., Potters, Louis, Rossi, Peter J., Showalter, Timothy N., Solanki, Abhishek A., Song, Daniel, Vanneste, Ben, Vigneault, Eric, Wojcieszek, Piotr A., Zelefsky, Michael J., Kamrava, Mitchell

“…•Salvage brachytherapy is safe and effective for radiorecurrent prostate cancer.•Thirty international experts completed a Delphi consensus study.•Consensus was…”
Get full text

Management of high-risk and post-operative non-metastatic prostate cancer in Catalonia: an expert Delphi consensus by Bonet, Marta, González, David, Baquedano, José-Enrique, García, Elena, Altabas, Manuel, Casas, Francesc, Feltes, Nicolás, Ferrer, Ferran, Foro, Palmira, Fuentes, Rafael, Galdeano, Manuel, Gomez, David, Henriquez, Ivan, Jové, Josep, Lozano, Joan, Maldonado, Xavier, Mases, Joel, Membrive, Ismael, Paredes, Saturio, Roselló, Àlvar, Sancho, Gemma, Mira, Moisés

“…Background To reach a consensus on recommendations for the management of high-risk and post-operative non-metastatic prostate cancer by a group of Radiation…”
Get full text

Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trial by Balana, Carmen, De Las Penas, Ramon, Sepúlveda, Juan Manuel, Gil-Gil, Miguel J., Luque, Raquel, Gallego, Oscar, Carrato, Cristina, Sanz, Carolina, Reynes, Gaspar, Herrero, Ana, Ramirez, Jose Luis, Pérez-Segura, Pedro, Berrocal, Alfonso, Vieitez, Jose Maria, Garcia, Almudena, Vazquez-Estevez, Sergio, Peralta, Sergi, Fernandez, Isaura, Henriquez, Ivan, Martinez-Garcia, Maria, De la Cruz, Juan Jose, Capellades, Jaume, Giner, Pilar, Villà, Salvador

“…We sought to determine the impact of bevacizumab on reduction of tumor size prior to chemoradiotherapy in unresected glioblastoma patients. Patients were…”
Get full text

Early PSA progression in abiraterone/enzalutamide-treated patients with metastatic castration-resistant prostate cancer by López-Campos, Fernando, Gomez-Iturriaga, Alfonso, Llacer Perez, Casilda, Henriquez, Ivan, Peleteiro, Paula, Lozano, Rebeca, Castaño, Ana, Romero-Laorden, Nuria, Molina-Cerrillo, Javier, Alvarez-Rodríguez, Sara, Piquer, Teresa, Navarro-Castellón, Joaquin, Conde-Moreno, Antonio José, Ramirez-Backhaus, Miguel, Barrionuevo, Patricia, García, Raquel, Pérez-Haro, María de los Llanos, Castro, Elena, Olmos, David, Lorente, David

“…Abstract only e16530 Background: Changes in PSA are widely used as a biomarker for the monitoring of treatment outcome in Metastatic Castration-Resistant…”
Get full text

Current and Emerging Therapies for Metastatic Castration-Resistant Prostate Cancer (mCRPC) by Henríquez, Iván, Roach, Mack, Morgan, Todd M., Bossi, Alberto, Gómez, Junior A., Abuchaibe, Oscar, Couñago, Felipe

“…Metastatic castration-resistant prostate cancer (mCRPC) encompasses a heterogeneous wide range of molecular tumor behavior and a high risk of progression…”
Get full text

PSMA PET/CT SUVmax as a prognostic biomarker in patients with metachronous metastatic hormone-sensitive prostate cancer (mHSPC) by Henríquez, Iván, Malave, Bárbara, Campos, Fernando López, Hidalgo, Elena Centelles, Muelas, Rodrigo, Ferrer, Carlos, Muñoz-Rodriguez, Jesús, Villamón, Agustina Méndez, Pascual, María Cerrolaza, Badia, Joan, Fuertes, Jordi, Hinojosa-Salas, Percy

“…Metastatic hormone-sensitive prostate cancer (mHSPC) is treatment-resistant and generally considered incurable. The development of prostate-specific membrane…”
Get full text

Salvage brachytherapy in prostate local recurrence after radiation therapy: predicting factors for control and toxicity by Henríquez, Iván, Sancho, Gemma, Hervás, Asunción, Guix, Benjamin, Pera, Joan, Gutierrez, Cristina, Abuchaibe, Oscar, Martínez-Monge, Rafael, Tormo, Alejandro, Polo, Alfredo

“…To evaluate efficacy and toxicity after salvage brachytherapy (BT) in prostate local recurrence after radiation therapy. Between 1993 and 2007, we…”
Get full text

Three linked nomograms for predicting biochemical failure in prostate cancer treated with radiotherapy plus androgen deprivation therapy by López-Torrecilla, Jose, Boladeras, Anna, Cabeza, María Angeles, Zapatero, Almudena, Jove, Josep, Esteban, Luis M., Henriquez, Ivan, Casaña, Manuel, González-San Segundo, Carmen, Gómez-Caamaño, Antonio, Mengual, Jose Luis, Hervás, Asunción, Muñoz, Julia Luisa, Sanz, Gerardo

“…Background Nomograms were established to predict biochemical recurrence (BCR) after radiotherapy (RT) with a low weight of the characteristic variables of RT…”
Get full text

Evaluation of PSA progression after initiation of enzalutamide or abiraterone: Real-world data on metastatic castration-resistant prostate cancer (mCRPC) by López-Campos, Fernando, Lorente, David, Llacer Perez, Casilda, Ramirez-Backhaus, Miguel, Peleteiro, Paula, Gomez-Iturriaga, Alfonso, Henriquez-López, Ivan, Lozano, Rebeca, Romero, Nuria, Alonso-Gordoa, Teresa, Molina-Cerrillo, Javier, Navarro-Castellón, Joaquin, Castaño, Ana, Pelari, Lira, Hernández-Corrales, Antonio, Morillo, Virginia, García, Raquel, Ferrer Albiach, Carlos, Castro, Elena, Olmos, David

“…Abstract only 5024 Background: PSA value is widely used for the monitoring of treatment outcome in mCRPC in the clinical real-world setting. Early PSA changes…”
Get full text

Treatment of keloids by high-dose-rate brachytherapy: A seven-year study by Guix, B, Henríquez, I, Andrés, A, Finestres, F, Tello, J I, Martínez, A

“…To analyze the results obtained in a prospective group of patients with keloid scars treated by high-dose-rate (HDR) brachytherapy with or without surgery. One…”
Get more information

101: Salvage Prostate Brachytherapy in Radiorecurrent Prostate Cancer: An International Delphi Consensus Study by Morton, Gerard, Chung, Hans T., Corkum, Mark T., Buyyounouski, Mark, Chang, Albert, Chung, Peter, Cox, Brett, Crook, Juanita, Davis, Brian, Frank, Steven, Henriquez, Iván, Horwitz, Eric, Hoskin, Peter, Hsu, I-Chow, Keyes, Mira, King, Martin, Kollmeier, Marissa, Krauss, Daniel, Kukielka, Andrzej, Orio, Peter, Pieters, Bradley, Potters, Louis, Rossi, Peter, Showalter, Timothy, Solanki, Abhishek, Song, Danny, Vanneste, Ben, Vigneault, Eric, Wojcieszek, Piotr, Zelefsky, Michael, Kamrava, Mitchell

Get full text

Salvage brachytherapy for prostate cancer biochemical recurrence after radiotherapy by Rubio, Alfredo Polo, López, Ivan J Henríquez

“…The best treatment option for patients with prostate cancer who experience local relapse after external beam radiation therapy remains uncertain. Salvage…”
Get full text